Source: Eur Respir J 2010; 36: 1113-1119



Rating:

Share or cite this content

Citations should be made in the following way:
Nave R., Watz H., Hoffmann H., Boss H., Magnussen H.. Deposition and metabolism of inhaled ciclesonide in the human lung. Eur Respir J 2010; 36: 1113-1119

Member's Comments

No comment yet.

Related content which might interest you: Uptake, retention and metabolism of ciclesonide in human alveolar epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Concentrations of ciclesonide and its metabolites in the human lung after inhalation of 1280 μg ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006 Effects of ciclesonide (CIC) on human adult lung fibroblasts functions involved in airway inflammation and remodeling Source: Eur Respir J 2006; 28: Suppl. 50, 101s Year: 2006 Glycosaminoglycan synthesis is modulated by ciclesonide in human lung cells Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004 In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slices Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004 HDAC2-independent anti-inflammatory effects of budesonide in human lung fibroblasts Source: Annual Congress 2011 - Recent developments in COPD Year: 2011 Lung deposition of inhaled radio-labelled human insulin Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Proteoglycan production in cultured human lung fibroblasts is synergistcally inhibited by combination of budesonide and formoterol Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003 Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Exposure of human subcutaneous adipose tissue and skeletal muscle tissue to unbound active drug after inhalation of high-dose ciclesonide or budesonide Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007 Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004 A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 High lung deposition of 99mTc-labelled ciclesonide administered via HFA-MDI to asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011 Unbound pharmacologically active metabolite des-CIC is not detectable in human skeletal muscle and subcutaneous adipose tissue after inhalation of high-dose ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 The lung microbiota changes associated with inhaled corticosteroid and azithromycin in murine model of COPD Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Budesonide esterification in human bronchial epithelial cells is not impaired by formoterol Source: Eur Respir J 2002; 20: Suppl. 38, 619s Year: 2002